Comparative Pharmacology
Head-to-head clinical analysis: RAUVAL versus SERPATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUVAL versus SERPATE.
RAUVAL vs SERPATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
50 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
Terminal half-life of 12-15 hours (range 10-18h) in adults; prolonged in renal impairment (up to 30h in severe cases).
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Primarily renal excretion of unchanged drug (60-80%); biliary/fecal elimination accounts for 15-20%.
Category C
Category C
Antihypertensive
Antihypertensive